Search
EHA-funded study in The Lancet Haematology: Economic Burden of Blood Disorders in EU is €23 billion
In Europe blood disorders affect around 80 million people. The total cost of blood disorders consists of healthcare expenditure (€15. 6 billion), productivity loss due to illness and mortality (€5. 6 billion), and the costs of informal care (€1.
Read moreEHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias
Dates: April 25-26, 2025
Location: to be announced
Chairs: K Döhner, P Vyas, and MT Voso
Collaborating SWG: EHA Specialized Working Group on Acute Myeloid Leukemia
Registration will be open soon
Program The EHA-SWG scientific meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid…
EU funding crucial in allowing medical researchers across member states to collaborate in the development of new treatments
In an article published in Science|Business, Prof.
Read moreA new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER!
A new form of inherited thrombocytopenia (ETV6-related thrombocytopenia, ETV6-RT): NEVER JUDGE A BOOK BY ITS COVER!
We recently discovered a new form of an inherited deficiency of platelets (inherited thrombocytopenia-IT), which is caused by mutations in the ETV6-gene.
EHA-PTHiT Hematology Tutorial on Novel Treatment Approaches in Hematologic Malignancies
EHA in collaboration with the Polish Society for Hematology and Transfusion (PTHiT) have decided to postpone this highly anticipated Hematology Tutorial to a future date, to be announced.
Read moreNon-EHA Funding Opportunities
Here you will find other interesting funding opportunities for European researchers in hematology. If you are interested in adding additional opportunities to this page, please contact research@ehaweb. org.
Read moreChairs and Members
ChairProf Raúl Córdoba (2020–2025 term)
Co-chairProf Valentín Goede
SWG Steering Committee
Sonja Zweegman (The Netherlands)—interest in multiple myeloma
Tamas Fulop (Canada)—interest in geriatrics and immunology
Giuseppe Rossi (Italy)—interest in indolent lymphomas
Dominique Bron (Belgium)—interest in lymphoma, CLL, and cognitive impairment
Sergio Storti (Italy)—interest in aggressive lymphomas
Lionel Ades…
Implementation of the new EU Regulation for In Vitro Diagnostic Medical Devices: a ticking time bomb for the diagnostic sector.
Urgent actions are needed now to prevent a collapse of diagnostic testing.
Read moreEvaluation of a single 1.000 mg iron dose as ferric carboxymaltose (FCM) for fatigue treatment in Iron deficient women – PREFER
Fatigue and iron deficiency are prevalent among women of childbearing age. This randomised, placebo-controlled study evaluated the effect of a single intravenous 1.
Read moreAdding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years
ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- »